NEJM.org
@nejm.org
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.
Follow @ai.nejm.org for medical AI content.
Follow @ai.nejm.org for medical AI content.
📖 Further reading
Original Article by N. Daneman et al.: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections nej.md/3Z5bTJD
Original Article by N. Daneman et al.: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections nej.md/3Z5bTJD
December 13, 2025 at 5:02 PM
📖 Further reading
Original Article by N. Daneman et al.: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections nej.md/3Z5bTJD
Original Article by N. Daneman et al.: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections nej.md/3Z5bTJD
A punch biopsy showed dermal infiltration by small, round, blue cells arranged in nests, with scant cytoplasm and frequent mitoses. Immunohistochemical testing for perinuclear CK20 and synaptophysin was positive. What is the most likely diagnosis? nej.md/IC12112025 2/2
December 12, 2025 at 8:02 PM
A punch biopsy showed dermal infiltration by small, round, blue cells arranged in nests, with scant cytoplasm and frequent mitoses. Immunohistochemical testing for perinuclear CK20 and synaptophysin was positive. What is the most likely diagnosis? nej.md/IC12112025 2/2
Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) nej.md/45OjEWN
Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS
Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 11, 2025 at 2:02 PM
Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) nej.md/45OjEWN
Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS
Subscribe to NEJM for the latest medical research: nej.md/subscribe